Skip to content
In conversation with... Rosie Bradley episode artwork

Mar 1, 2022 4 min

In conversation with... Rosie Bradley

from Listen to The Lancet Oncology Hosted by The Lancet

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

In conversation with... Rosie Bradley

0:00 4:33

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 4 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on March 1, 2022.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.